lol...i know nothing about this stock so lets start...
190M shares....50M options....maybe $12M in cash now...
fully diluted market cap at $2 is $480M...
seeking market share in US$4 billion global CML market...
��Gleevec approved for CML in 2001 ��By 2004 estimates that up to 30% of CML patients are resistant to Gleevec ��2004 sales of GleevecUS$630M for CML & US$1,400M off-label ��Research indicates that majority of CML patients will eventually develop resistance to GleevecUNMET
CXS Price at posting:
0.0¢ Sentiment: Hold Disclosure: Held
